Treatment
- abiraterone
- anastrozole
- bicalutamide
- capecitabine
- CAPOX
- carboplatin
- cetuximab
- cisplatin
- crizotinib
- dacarbazine
- docetaxel
- doxorubicin
- epirubicin
- erlotinib
- everolimus
- exemestane
- fluorouracil
- flutamide
- FOLFOX
- FOLFIRI
- fulvestrant
- gefitinib
- gemcitabine
- goserelin
- imatinib
- irinotecan
- lapatinib
- letrozole
- leuprolide
- liposomal doxorubicin
- megestrol acetate
- nab-paclitaxel
- oxaliplatin
- paclitaxel
- panitumumab
- pemetrexed
- pertuzumab
- sorafenib
- sunitinib
- tamoxifen
- temozolomide
- temsirolimus
- topotecan
- toremifene
- trastuzumab
- vemurafenib
cisplatin
Cisplatin causes a platinum atom to bind to bases, most often guanine, leading to the formation of adducts. These adducts interfere with mitosis and elicit the production of
DNA repair enzymes which induce apoptosis. While cisplatin is frequently designated
as an alkylating agent, it has no alkyl group and cannot perform alkylating reactions.
Consequently, it is more correctly classified as alkylating-like.
Cisplatin is indicated* for treatment of metastatic testicular cancer, metastatic ovarian cancer and advanced bladder cancer.
*Please refer to full prescribing information/package insert for precise indications.
Associated Tumor Types
- Testicular cancer
- Ovarian cancer
- Breast cancer
- Head and neck cancer
- Bladder cancer
- Non-small cell lung cancer